CERE - Cerevel Therapeutics Holdings, Inc. Stock Price, Fair Value and News

42.06USD-0.13 (-0.31%)Market Closed

Market Summary

USD42.06-0.13

Market Closed

-0.31%

CERE Stock Price

View Fullscreen

CERE RSI Chart

CERE Valuation

Market Cap

7.7B

Price/Earnings (Trailing)

-16.64

Price/Sales (Trailing)

34.2K

EV/EBITDA

-17.32

Price/Free Cashflow

-20.67

CERE Price/Sales (Trailing)

CERE Profitability

EBT Margin

-205300.45%

Return on Equity

-81.58%

Return on Assets

-40.85%

Free Cashflow Yield

-4.84%

CERE Fundamentals

CERE Revenue

Revenue (TTM)

224.0K

CERE Earnings

Earnings (TTM)

-460.5M

Earnings Growth (Yr)

-26.49%

Earnings Growth (Qtr)

0.56%

Breaking Down CERE Revenue

Last 7 days

-0.7%

Last 30 days

0.4%

Last 90 days

-1.3%

Trailing 12 Months

32.3%

How does CERE drawdown profile look like?

CERE Financial Health

Current Ratio

10.22

Debt/Equity

0.6

Debt/Cashflow

-1.09

CERE Investor Care

Shares Dilution (1Y)

16.17%

Diluted EPS (TTM)

-2.73

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	0	0	0	0
2021	0	0	0	0
2020	1.3M	1.0M	489.6K	224.0K
2019	0	0	0	1.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cerevel Therapeutics Holdings, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	coles n anthony	sold	-2,116,640	42.3328	-50,000	-
Apr 01, 2024	coles n anthony	acquired	175,000	3.5	50,000	-
Mar 04, 2024	coles n anthony	acquired	175,000	3.5	50,000	-
Mar 04, 2024	coles n anthony	sold	-2,050,550	41.011	-50,000	-
Feb 29, 2024	coles n anthony	acquired	175,000	3.5	50,000	-
Feb 29, 2024	coles n anthony	sold	-2,057,890	41.1578	-50,000	-
Feb 20, 2024	perceptive advisors llc	gifted	-	-	-170,317	-
Feb 07, 2024	renger john	sold	-89,776	41.5441	-2,161	chief scientific officer
Feb 07, 2024	coles n anthony	sold	-104,110	41.5441	-2,506	-
Feb 06, 2024	renger john	acquired	-	-	5,020	chief scientific officer

Which funds bought or sold CERE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	GROUP ONE TRADING, L.P.	added	34.51	290,405	1,142,010	-%
May 10, 2024	Pacer Advisors, Inc.	new	-	43,749	43,749	-%
May 10, 2024	CREDIT SUISSE AG/	reduced	-36.03	-2,679,950	4,718,770	-%
May 10, 2024	Scarborough Advisors, LLC	unchanged	-	-26.00	8,454	-%
May 10, 2024	DIMENSIONAL FUND ADVISORS LP	new	-	504,915	504,915	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	11.41	94,518	948,581	-%
May 10, 2024	PNC Financial Services Group, Inc.	reduced	-99.82	-275,093	507	-%
May 10, 2024	Covestor Ltd	reduced	-3.05	-1,000	12,000	0.01%
May 10, 2024	CITIGROUP INC	added	270	58,395,500	80,107,100	0.05%
May 10, 2024	Greenland Capital Management LP	new	-	378,739	378,739	0.04%

Are Funds Buying or Selling CERE?

Are funds buying CERE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CERE

No. of Funds

Unveiling Cerevel Therapeutics Holdings, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 10, 2024	fmr llc	-	0	SC 13G/A
Dec 08, 2023	bc perception holdings, lp	36.4%	65,679,781	SC 13D/A
Oct 18, 2023	bc perception holdings, lp	36.5%	65,679,781	SC 13D/A
Oct 18, 2023	pfizer inc	15.4%	27,349,211	SC 13D/A
Oct 17, 2023	perceptive advisors llc	6.2%	10,965,193	SC 13D/A
Apr 25, 2023	perceptive advisors llc	6.3%	9,918,068	SC 13D/A
Apr 21, 2023	perceptive advisors llc	6.4%	10,088,385	SC 13D
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Aug 18, 2022	bc perception holdings, lp	38.9%	60,632,356	SC 13D/A
Apr 07, 2022	pfizer inc	18.5%	27,349,211	SC 13D/A

Recent SEC filings of Cerevel Therapeutics Holdings, Inc.

View All Filings

Date Filed	Form Type	Document
May 10, 2024	144	Notice of Insider Sale Intent
May 10, 2024	SC 13G/A	Major Ownership Report
May 08, 2024	10-Q	Quarterly Report
Apr 26, 2024	10-K/A	Annual Report
Apr 03, 2024	4	Insider Trading
Apr 01, 2024	144	Notice of Insider Sale Intent
Mar 06, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	144	Notice of Insider Sale Intent
Feb 29, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Cerevel Therapeutics Holdings, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	9.94%	-6.22%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	-2.91%	-28.25%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-8.16%	-14.11%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	-3.25%	-16.30%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	1.06%	107.74%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-22.86%	-53.47%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	1.43%	-8.15%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-5.83%	-38.95%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-16.20%	-29.75%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	-0.89%	-10.62%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	1.13%	-50.28%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	16.73%	369.82%	-13.59	481.06	-77.61%	33.36%
INO	265.7M	4.9M	-3.87%	15.02%	-1.97	54.6	-54.97%	51.71%
IBIO	6.3M	2.1M	-13.36%	77.36%	-0.23	2.14	-13.45%	66.37%

Cerevel Therapeutics Holdings, Inc. News

Latest updates

Cerevel Therapeutics Holdings, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2022Q3	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q2	2020Q1	2019Q4
Revenue	49.7%	3,992	2,666	1,341	15.00	14.00	2,502	4,990	4,990	-	-
Operating Expenses	74.3%	95,065	54,527	50,510	50,571	41,896	34,362	35,156	-	37,702	-
S&GA Expenses	64.8%	23,680	14,368	13,216	14,010	22,447	10,336	12,973	57.00	10,743	-
R&D Expenses	77.8%	71,385	40,159	37,294	36,561	30,135	24,026	22,183	-	26,959	-
Interest Expenses	9792.3%	1,286	13.00	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-3.00	-5.00	-16.00	-	-	-
Earnings Before Taxes	-61.0%	-99,938	-62,059	-53,239	-50,981	-33,214	-39,045	-26,733	-	-53,208	-
EBT Margin	-59.3%	-1.42	-890.59*	-787.85*	-	-	-	-	-	-	-
Net Income	-61.0%	-99,938	-62,059	-53,239	-50,981	-86,327	-39,040	-26,717	-57.11	-53,208	-
Net Income Margin	-25.8%	-1.42	-1.13	-1.02	-	-	-	-	-	-	-
Free Cashflow	-79.2%	-80,576	-44,964	-49,191	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																		(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q2	2019Q4
Assets	-9.3%	1,127	1,243	822	894	930	1,018	1,094	597	619	689	733	391	408	445	151	151	151	121
Current Assets	-14.6%	860	1,007	688	752	841	906	999	540	554	578	675	332	350	391	1.00	2.00	2.00	87.00
Cash Equivalents	-22.6%	322	416	156	176	154	137	249	138	92.00	197	670	327	343	388	13.00	18.00	1.00	84.00
Net PPE	-2.8%	25.00	26.00	27.00	27.00	27.00	27.00	28.00	29.00	30.00	28.00	28.00	28.00	28.00	24.00	-	-	-	1.00
Liabilities	-1.2%	563	570	549	544	499	497	490	144	97.00	110	104	97.00	68.00	61.00	8.00	6.00	6.00	43.00
Current Liabilities	-8.8%	84.00	92.00	79.00	66.00	63.00	73.00	60.00	57.00	35.00	43.00	31.00	29.00	34.00	30.00	3.00	0.00	0.00	15.00
Long Term Debt	0.1%	338	337	337	336	336	335	335	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	337	337	336	336	335	335	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-16.2%	564	674	273	351	432	521	603	453	521	579	629	294	340	385	5.00	4.00	5.00	78.00
Retained Earnings	-9.4%	-1,532	-1,400	-1,267	-1,171	-1,072	-967	-874	-775	-684	-616	-557	-495	-441	-390	-3.12	-0.23	-0.06	-244
Additional Paid-In Capital	1.2%	2,098	2,073	1,539	1,521	1,500	1,486	1,473	1,220	1,207	1,196	1,187	789	782	775	8.00	5.00	5.00	322
Accumulated Depreciation	11.4%	14.00	13.00	11.00	10.00	9.00	7.00	6.00	5.00	4.00	3.00	2.00	1.00	0.00	0.00	-	-	-	0.00
Shares Outstanding	0.3%	182	181	158	157	157	157	152	148	148	137	133	127	-	-	-	-	-	-
Float	-	-	-	-	2,200	-	-	-	1,576	-	-	-	995	-	-	-	173,420	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-22.8%	-119,669	-97,420	-72,631	-77,327	-94,923	-87,478	-80,405	-57,656	-67,648	-52,744	-43,776	-45,608	-36,418	-79,121	-20,082	-446	-424	-29,454	-
Share Based Compensation	-17.0%	20,932	25,222	17,088	14,508	12,592	10,378	9,696	10,148	8,558	6,486	6,134	5,184	6,137	657	3,471	3,423	-	2,970	-
Cashflow From Investing	112.8%	19,165	-150,208	51,394	61,753	110,783	-26,732	-387,854	64,294	-38,542	-426,230	-1,188	-3,583	-4,660	136,279	-	-149,500	-149,500	-2,556	-
Cashflow From Financing	-99.1%	4,475	508,372	1,195	37,614	1,435	2,131	578,641	39,816	2,603	2,316	387,580	32,964	742	279,316	-262	151,209	151,325	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CERE Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 106,425	$ 78,181
General and administrative	36,231	21,370
Total operating expenses	142,656	99,551
Loss from operations	(142,656)	(99,551)
Interest income, net	14,455	9,076
Interest expense	(2,652)	(2,636)
Other income (expense), net (Notes 5 and 7)	(921)	(11,090)
Loss before income taxes	(131,774)	(104,201)
Income tax benefit (provision), net	(138)	(85)
Net loss	$ (131,912)	$ (104,286)
Net loss per share, basic	$ (0.73)	$ (0.67)
Net loss per share, diluted	$ (0.73)	$ (0.67)
Weighted-average shares used in calculating net loss per share, basic	181,610,675	156,648,365
Weighted-average shares used in calculating net loss per share, diluted	181,610,675	156,648,365
Comprehensive loss:
Net loss	$ (131,912)	$ (104,286)
Other comprehensive income (loss):
Changes in fair value attributable to instrument-specific credit risk (Notes 5 and 7)	(920)	(906)
Unrealized gains (losses) on securities available-for-sale	(1,940)	1,497
Total other comprehensive income (loss)	(2,860)	591
Comprehensive loss	$ (134,772)	$ (103,695)

CERE Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 320,436	$ 416,465
Marketable securities	525,858	574,500
Prepaid expenses and other current assets	13,283	15,973
Total current assets	859,577	1,006,938
Marketable securities	218,591	185,199
Property and equipment, net	24,929	25,647
Operating lease assets	19,667	20,125
Restricted cash	1,960	1,960
Other long-term assets	2,619	3,429
Total assets	1,127,343	1,243,298
Current liabilities:
Accounts payable	10,839	11,863
Accrued expenses and other current liabilities	69,750	76,912
Operating lease liabilities, current portion	3,515	3,404
Total current liabilities	84,104	92,179
Operating lease liabilities, net of current portion	26,866	27,786
Financing liability, related party (Notes 5, 7 and 15)	56,999	56,082
Financing liability (Notes 5 and 7)	56,999	56,082
2027 convertible senior notes, net (Note 6)	337,920	337,424
Total liabilities	562,888	569,553
Commitments and contingencies (Notes 13 and 14)
Stockholders’ equity:
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2024 and December 31, 2023
Common stock, $0.0001 par value: 500,000,000 shares authorized; 181,888,631 and 181,362,064 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	18	18
Additional paid-in capital	2,098,035	2,072,553
Accumulated other comprehensive income (loss)	(1,089)	1,771
Accumulated deficit	(1,532,509)	(1,400,597)
Total stockholders’ equity	564,455	673,745
Total liabilities and stockholders’ equity	$ 1,127,343	$ 1,243,298

About Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Ronald C. Renaud Jr., M.B.A., MBA
WEBSITE	cerevel.com
INDUSTRY	Biotechnology
EMPLOYEES	322

Cerevel Therapeutics Holdings, Inc. Frequently Asked Questions

What is the ticker symbol for Cerevel Therapeutics Holdings, Inc.? What does CERE stand for in stocks?

CERE is the stock ticker symbol of Cerevel Therapeutics Holdings, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cerevel Therapeutics Holdings, Inc. (CERE)?

As of Fri May 10 2024, market cap of Cerevel Therapeutics Holdings, Inc. is 7.69 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CERE stock?

You can check CERE's fair value in chart for subscribers.

What is the fair value of CERE stock?

You can check CERE's fair value in chart for subscribers. The fair value of Cerevel Therapeutics Holdings, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cerevel Therapeutics Holdings, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CERE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cerevel Therapeutics Holdings, Inc. a good stock to buy?

The fair value guage provides a quick view whether CERE is over valued or under valued. Whether Cerevel Therapeutics Holdings, Inc. is cheap or expensive depends on the assumptions which impact Cerevel Therapeutics Holdings, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CERE.

What is Cerevel Therapeutics Holdings, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 10 2024, CERE's PE ratio (Price to Earnings) is -16.69 and Price to Sales (PS) ratio is 34.21 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CERE PE ratio will change depending on the future growth rate expectations of investors.